MetaADEDB 2.0 @ LMMD
Apomorphine
(SKYZYDSNJIOXRL-BTQNPOSSSA-N)
Structure
SMILES
CN1CCc2c3[C@H]1Cc1ccc(c(c1c3ccc2)O)O.Cl
Molecular Formula:
C17H18ClNO2
Molecular Weight:
303.783
Log P:
3.5898
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
3
TPSA:
43.7
CAS Number(s):
314-19-2; 41372-20-7
Synonym(s)
1.
Apomorphine
2.
Apokinon
3.
Apomorphin-Teclapharm
4.
Apomorphine Chloride
5.
Apomorphine Hydrochloride
6.
Apomorphine Hydrochloride Anhydrous
7.
Apomorphine Hydrochloride, Anhydrous
8.
Apomorphine Hydrochloride, Hemihydrate
9.
Britaject
10.
Apomorphin Teclapharm
External Link(s)
MeSHD001058
PubChem Compound9410
BindingDB50367948
CHEMBLCHEMBL1616
Therapeutic Target DatabaseD0B6QP
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1NoduleFAERS: 10US FAERS
2SomnolenceFAERS: 10US FAERS
3Drug ineffectiveFAERS: 8US FAERS
4Cerebrovascular accidentFAERS: 6US FAERS
5Injection site noduleFAERS: 6US FAERS
6MalaiseFAERS: 6US FAERS
7TremorFAERS: 6US FAERS
8General physical health deteriorationFAERS: 5US FAERS
9HypotensionFAERS: 5US FAERS
10PanniculitisFAERS: 5US FAERS
11Incorrect dose administeredFAERS: 4US FAERS
12InfectionFAERS: 4US FAERS
13Injection site infectionFAERS: 4US FAERS
14NauseaFAERS: 4US FAERS
15Neuroleptic Malignant SyndromeFAERS: 4US FAERS
16Skin necrosisFAERS: 4US FAERS
17Weight decreasedFAERS: 4US FAERS
18Cardiac ArrestFAERS: 3US FAERS
19DementiaFAERS: 3US FAERS
20Drug administration errorFAERS: 3US FAERS
21EosinophiliaFAERS: 3US FAERS
22InflammationFAERS: 3US FAERS
23Injection site abscessFAERS: 3US FAERS
24Injection site bruisingFAERS: 3US FAERS
25Injection site necrosisFAERS: 3US FAERS
26Intestinal ObstructionFAERS: 3US FAERS
27Muscle RigidityFAERS: 3US FAERS
28Unresponsive to stimuliFAERS: 3US FAERS
29VomitingFAERS: 3US FAERS
30AstheniaFAERS: 2US FAERS
31Blood iron decreasedFAERS: 2US FAERS
32Cerebral InfarctionFAERS: 2US FAERS
33CystitisFAERS: 2US FAERS
34Depressed Level of ConsciousnessFAERS: 2US FAERS
35DermatitisFAERS: 2US FAERS
36DizzinessFAERS: 2US FAERS
37Drug DependenceFAERS: 2US FAERS
38FatigueFAERS: 2US FAERS
39FlushingFAERS: 2US FAERS
40HeadacheFAERS: 2US FAERS
41HyperkinesiaFAERS: 2US FAERS
42HypersensitivityFAERS: 2US FAERS
43Incorrect route of drug administrationFAERS: 2US FAERS
44Injection site extravasationFAERS: 2US FAERS
45Injection site massFAERS: 2US FAERS
46Malabsorption from injection siteFAERS: 2US FAERS
47Medication ErrorFAERS: 2US FAERS
48OverdoseFAERS: 2US FAERS
49PallorFAERS: 2US FAERS
50Post procedural complicationFAERS: 2US FAERS
51Product name confusionFAERS: 2US FAERS
52Product quality issueFAERS: 2US FAERS
53Skin UlcerFAERS: 2US FAERS
54SyncopeFAERS: 2US FAERS
55Urinary tract infectionFAERS: 2US FAERS
56Wrong technique in drug usage processFAERS: 2US FAERS
57Abdominal PainFAERS: 1US FAERS
58AgitationFAERS: 1US FAERS
59AlopeciaFAERS: 1US FAERS
60Altered state of consciousnessFAERS: 1US FAERS
61Angina PectorisFAERS: 1US FAERS
62AnxietyFAERS: 1US FAERS
63ApathyFAERS: 1US FAERS
64Application site woundFAERS: 1US FAERS
65AsthmaFAERS: 1US FAERS
66AtaxiaFAERS: 1US FAERS
67Atrial FibrillationFAERS: 1US FAERS
68Back PainFAERS: 1US FAERS
69Blood glucose decreasedFAERS: 1US FAERS
70Blood pressure fluctuationFAERS: 1US FAERS
71Blood sodium increasedFAERS: 1US FAERS
72Bone erosionFAERS: 1US FAERS
73BradycardiaFAERS: 1US FAERS
74BradykinesiaFAERS: 1US FAERS
75BronchitisFAERS: 1US FAERS
76CamptocormiaFAERS: 1US FAERS
77CatarrhFAERS: 1US FAERS
78CellulitisFAERS: 1US FAERS
79Chest PainFAERS: 1US FAERS
80CholecystitisFAERS: 1US FAERS
81ChromaturiaFAERS: 1US FAERS
82Circumstance or information capable of leading to device use errorFAERS: 1US FAERS
83Coma scale abnormalFAERS: 1US FAERS
84DiplopiaFAERS: 1US FAERS
85DroolingFAERS: 1US FAERS
86Drug abuseFAERS: 1US FAERS
87DysgeusiaFAERS: 1US FAERS
88DyspepsiaFAERS: 1US FAERS
89DysphemiaFAERS: 1US FAERS
90DystoniaFAERS: 1US FAERS
91DysuriaFAERS: 1US FAERS
92EpilepsyFAERS: 1US FAERS
93ErysipelasFAERS: 1US FAERS
94ErythemaFAERS: 1US FAERS
95Feeling abnormalFAERS: 1US FAERS
96FractureFAERS: 1US FAERS
97Freezing phenomenonFAERS: 1US FAERS
98Gait inabilityFAERS: 1US FAERS
99Gastric DilatationFAERS: 1US FAERS
100Gastrointestinal inflammationFAERS: 1US FAERS
101Gaze palsyFAERS: 1US FAERS
102General physical condition abnormalFAERS: 1US FAERS
103Hilar lymphadenopathyFAERS: 1US FAERS
104HyperventilationFAERS: 1US FAERS
105IleusFAERS: 1US FAERS
106IncoherentFAERS: 1US FAERS
107IncontinenceFAERS: 1US FAERS
108Incorrect dose administered by deviceFAERS: 1US FAERS
109Incorrect drug administration durationFAERS: 1US FAERS
110Infusion site infectionFAERS: 1US FAERS
111Infusion site necrosisFAERS: 1US FAERS
112Initial insomniaFAERS: 1US FAERS
113Injection site erythemaFAERS: 1US FAERS
114Injection site vesiclesFAERS: 1US FAERS
115Injection site warmthFAERS: 1US FAERS
116Intentional product use issueFAERS: 1US FAERS
117LethargyFAERS: 1US FAERS
118Lower respiratory tract infectionFAERS: 1US FAERS
119Memory impairmentFAERS: 1US FAERS
120MultimorbidityFAERS: 1US FAERS
121Musculoskeletal stiffnessFAERS: 1US FAERS
122NarcolepsyFAERS: 1US FAERS
123NecrosisFAERS: 1US FAERS
124NocturiaFAERS: 1US FAERS
125Ocular icterusFAERS: 1US FAERS
126PainFAERS: 1US FAERS
127Pancreatic carcinomaFAERS: 1US FAERS
128Pelvic floor dyssynergiaFAERS: 1US FAERS
129PharyngitisFAERS: 1US FAERS
130PneumoniaFAERS: 1US FAERS
131Reduced facial expressionFAERS: 1US FAERS
132Respiratory DepressionFAERS: 1US FAERS
133Retinal DetachmentFAERS: 1US FAERS
134RhinitisFAERS: 1US FAERS
135SepsisFAERS: 1US FAERS
136Septic ShockFAERS: 1US FAERS
137Skin IndurationFAERS: 1US FAERS
138Skin noduleFAERS: 1US FAERS
139SubileusFAERS: 1US FAERS
140Therapy changeFAERS: 1US FAERS
141ThrombosisFAERS: 1US FAERS
142Tonic clonic movementsFAERS: 1US FAERS
143Transaminases increasedFAERS: 1US FAERS
144Urinary IncontinenceFAERS: 1US FAERS
145WheezingFAERS: 1US FAERS
146Wound necrosisFAERS: 1US FAERS
147YawningFAERS: 1US FAERS
148jaundiceFAERS: 1US FAERS
149skin abrasionFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.